Elsevier

Human Pathology

Volume 19, Issue 12, December 1988, Pages 1403-1416
Human Pathology

The pathology of combined heart-lung transplantation: An autopsy study*

https://doi.org/10.1016/S0046-8177(88)80233-8Get rights and content

Clinical heart-lung transplantation (HLT) began at Stanford University (Stanford, CA) in 1981, and since then, over 40 HLTs have been performed. There is now a worldwide total of 250 HLTs. While much of the pathology that occurs in patients receiving an HLT is similar to that which develops in patients with other transplanted organ systems, these patients also develop unique clinical complications and pathologic processes that deserve emphasis. We report the autopsy findings of 20 HLT recipients, of whom 12 died in hospital one day to 4 months post-HLT. A major contributing factor in five of these postoperative deaths was pleural hemorrhage from adhesions due to prior chest surgery. Overwhelming viral and fungal infections accounted for six deaths. The seventh patient died as a result of adult respiratory distress syndrome (ARDS). Two patients showed histologic evidence of the reimplantation response. Six long-term survivors died (mean survival, 22 months) with obliterative bronchiolitis (OB). In four patients, OB was the immediate cause of death, while one patient died of an intercurrent myocardial infarct, and the other patient died of complications from an appendectomy. Two long-term survivors died without OB, one of iatrogenic causes at 63 months and the second due to unexplained ARDS at 52 months. Both patients without OB had virtually normal underlying pulmonary parenchyma. All of the long-term survivors had either coronary arterial or pulmonary vascular intimal sclerosis, and renal lesions attributable to cyclosporine A toxicity. Although histologic features of mild acute pulmonary and cardiac rejection were observed in four patients overall, these did not contribute to the cause of death in any case. Although OB is a major threat to its success, HLT is a viable option for patients with endstage pulmonary disease.

References (50)

  • HarjulaA et al.

    Proper donor selection for heart-lung transplantation—the Stanford experience

    J Thorac Cardiovasc Surg

    (1987)
  • BillinghamME

    Diseases of the transplanted heart

  • GrebeS et al.

    Graft-versus-host reactions: A review

    Adv Immunol

    (1976)
  • EplerG et al.

    The spectrum of bronchiolitis obliterans

    Chest

    (1983)
  • VeithF et al.

    Diagnosis and reversal of rejection in experimental and clinical lung allografts

    Ann Thorac Surg

    (1973)
  • StarzlTE et al.

    Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

    Lancet

    (1984)
  • BillinghamME

    Some recent advances in cardiac pathology

    Hum Pathol

    (1979)
  • ReitzB et al.

    Heart and lung transplantation: Autotransplantation and allotransplantation in primates with extended survival

    J. Thorac Cardiovasc Surg

    (1980)
  • ReitzB

    Heart-lung transplantation: A review

    J Heart Transplant

    (1982)
  • JamiesonS et al.

    Clinical heart-lung transplantation

    Tranplantation

    (1984)
  • KayeMP

    The registry of the International Society for Heart Transplantation: Fourth official report—1985

    J Heart Transplant

    (1987)
  • JamiesonSW et al.

    Procurement of organs for combined heart-lung transplantation

  • Glanville AR, Baldwin JC, Tazellar H, et al. Late onsetobliterative bronchiolitis post-heart-lung transplantation:...
  • GlanvilleAR et al.

    Obliterative bronchiolitis after heart-lung transplantation: Apparent arrest by augmented immunosuppression

    Ann Intern Med

    (1987)
  • BurkeCM et al.

    The spectrum of cytomegalovirus infection following human heart-lung transplantation

    J Heart Transplant

    (1986)
  • Cited by (0)

    *

    Presented in part at the United States-Canadian Division ofthe International Academy of Pathology Annual Meeting, Washington, DC, February 1988.

    1

    From the Departments of Pathology, Stanford University Medical Center, Stanford, CA; and the Department of Pathology, Presbyterian University Hospital of Pittsburgh.

    View full text